Zogenix Stock Price, News & Analysis (NASDAQ:ZGNX)

$36.55 -0.20 (-0.54 %)
(As of 11/17/2017 04:00 PM ET)
Previous Close$36.55
Today's Range$37.00 - $36.00
52-Week Range$7.70 - $42.60
Volume389,117 shs
Average Volume662,200 shs
Market Capitalization$1.17 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.02

About Zogenix (NASDAQ:ZGNX)

Zogenix logoZogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome. ZX008 has received orphan drug designation in the United States and European Union (EU), for the treatment of Dravet syndrome. The Company has an additional product candidate, Relday (risperidone once-monthly long-acting injectable) for the treatment of schizophrenia. Relday is a long-acting injectable formulation of risperidone. Risperidone is used to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers 13 years of age and older. It has completed the Phase I program for Relday.


Industry, Sector and Symbol:
  • Industry: Bio Medical Devices
  • Sub-Industry: Pharmaceuticals
  • Sector: Bio Medical Devices
  • Symbol: NASDAQ:ZGNX
  • CUSIP: 98978L10
  • Web: www.zogenix.com
Debt:
  • Debt-to-Equity Ratio: 0.23%
  • Current Ratio: 2.71%
  • Quick Ratio: 2.71%
Sales & Book Value:
  • Annual Sales: $28.85 million
  • Price / Sales: 43.39
  • Book Value: $1.74 per share
  • Price / Book: 21.01
Profitability:
  • Trailing EPS: ($4.39)
  • Net Income: ($69,700,000.00)
  • Net Margins: -309.76%
  • Return on Equity: -99.61%
  • Return on Assets: -44.17%
Misc:
  • Employees: 67
  • Outstanding Shares: 34,250,000
 

Frequently Asked Questions for Zogenix (NASDAQ:ZGNX)

What is Zogenix's stock symbol?

Zogenix trades on the NASDAQ under the ticker symbol "ZGNX."

How were Zogenix's earnings last quarter?

Zogenix, Inc. (NASDAQ:ZGNX) released its earnings results on Tuesday, August, 8th. The company reported ($0.90) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.89) by $0.01. The business earned $7.10 million during the quarter, compared to analysts' expectations of $3.48 million. Zogenix had a negative return on equity of 99.61% and a negative net margin of 309.76%. The firm's quarterly revenue was up 238.1% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.76) earnings per share. View Zogenix's Earnings History.

Where is Zogenix's stock going? Where will Zogenix's stock price be in 2017?

5 Wall Street analysts have issued twelve-month price targets for Zogenix's shares. Their predictions range from $28.00 to $55.00. On average, they expect Zogenix's stock price to reach $46.00 in the next year. View Analyst Ratings for Zogenix.

What are Wall Street analysts saying about Zogenix stock?

Here are some recent quotes from research analysts about Zogenix stock:

  • 1. Mizuho analysts commented, "We view the readout as impressive, but expect in real world application, a small percentage (~10-15%) of patients may not tolerate the therapy well. We further believe ZX-008 has better efficacy than GW Pharma’s competing drug, Epidiolex (GWPH, non-rated) NDA filing expected 2H2018. Zogenix’s pivotal phase III program for ZX008 is in DS comprises Study 1 and 1504. Data from both trials will be used in the NDA registration for the US." (9/29/2017)
  • 2. According to Zacks Investment Research, "Zogenix, Inc. is a pharmaceutical company engaged in the development and commercialization of treatment products for central nervous system disorders and pain. Its first commercial product, Sumavel™ DosePro™ is a needle-free Delivery System used in the treatment of acute migraine and cluster headache in a pre-filled, single-use delivery system. Its lead product candidate, ZX002, is a novel, oral and single-entity controlled-release formulation of hydrocodone used for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. Zogenix, Inc. is headquartered in San Diego, CA. " (9/1/2017)
  • 3. Aegis analysts commented, "adjunctive anti-epileptic therapy."Yang comments, "Study 1504 - a two cohort study to assess ZX008 as an adjunctive antiepileptic therapy. Designed as a multi-center study, 1504 is portioned into two cohorts that are a part of the phase III program for ZX008 in Dravet Syndrome. The first cohort assessed the pharmacokinetics and safety profile of ZX008 (fenfluramine hydrochloride), valproate, and clobazam when administered with stiripentol. In assessing these two aspects, cohort 1 served its primary purpose - identify the appropriate dosage of ZX008 to be used in the second cohort of the trial (0.5 mg/kg/day). Cohort 2 is designed as a double-blind, placebocontrolled trial randomizing 70 patients 1:1 (ZX008:placebo) after a 6 week baseline observation period. After a 3 week titration period, patients will receive either 0.5 mg/kg/day of ZX008 or equivalent placebo before being assessed at 12 weeks. The primary endpoint for cohort 2 is change from baseline in frequency of convulsive seizures, the same as study 1501 and 1502. All patients enrolled in the "stiripentol incomplete responder" trial will remain on their stable stiripentol drug regimen in addition to receiving either ZX008 or placebo." (2/14/2017)

Who are some of Zogenix's key competitors?

Who are Zogenix's key executives?

Zogenix's management team includes the folowing people:

  • Cam L. Garner, Independent Chairman of the Board (Age 67)
  • Stephen J. Farr Ph.D., President, Chief Executive Officer, Director (Age 56)
  • Michael P. Smith, Chief Financial Officer, Executive Vice President, Treasurer, Secretary (Age 48)
  • Gail M. Farfel Ph.D., Executive Vice President, Chief Development Officer (Age 51)
  • Bradley S. Galer M.D., Executive Vice President and Chief Medical Officer (Age 53)
  • Thierry J P Darcis, Executive Vice President and General Manager of Europe of Brabant Pharma Ltd.
  • James B. Breitmeyer M.D., Ph.D., Director (Age 61)
  • Roger L. Hawley, Director (Age 63)
  • Erle T. Mast, Independent Director (Age 52)
  • Mark C. Wiggins, Independent Director (Age 59)

Who owns Zogenix stock?

Zogenix's stock is owned by many different of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (10.72%), VHCP Management II LLC (2.65%), Dimensional Fund Advisors LP (1.35%), JPMorgan Chase & Co. (0.73%), Candriam Luxembourg S.C.A. (0.53%) and Point72 Asset Management L.P. (0.44%). Company insiders that own Zogenix stock include Life Sciences Maste Perceptive, Renee P Tannenbaum and Roger Hawley. View Institutional Ownership Trends for Zogenix.

Who sold Zogenix stock? Who is selling Zogenix stock?

Zogenix's stock was sold by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., Candriam Luxembourg S.C.A., Iguana Healthcare Management LLC, JPMorgan Chase & Co., Gagnon Securities LLC, Wells Fargo & Company MN, California State Teachers Retirement System and Dimensional Fund Advisors LP. View Insider Buying and Selling for Zogenix.

Who bought Zogenix stock? Who is buying Zogenix stock?

Zogenix's stock was bought by a variety of institutional investors in the last quarter, including VHCP Management II LLC, Perceptive Advisors LLC, Point72 Asset Management L.P., Sphera Funds Management LTD., EAM Investors LLC, OxFORD Asset Management LLP, Granite Point Capital Management L.P. and Bank of New York Mellon Corp. Company insiders that have bought Zogenix stock in the last two years include Life Sciences Maste Perceptive, Renee P Tannenbaum and Roger Hawley. View Insider Buying and Selling for Zogenix.

How do I buy Zogenix stock?

Shares of Zogenix can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zogenix's stock price today?

One share of Zogenix stock can currently be purchased for approximately $36.55.

How big of a company is Zogenix?

Zogenix has a market capitalization of $1.17 billion and generates $28.85 million in revenue each year. The company earns ($69,700,000.00) in net income (profit) each year or ($4.39) on an earnings per share basis. Zogenix employs 67 workers across the globe.

How can I contact Zogenix?

Zogenix's mailing address is 5858 Horton St Ste 455, EMERYVILLE, CA 94608-2072, United States. The company can be reached via phone at +1-510-5508300 or via email at [email protected]


MarketBeat Community Rating for Zogenix (NASDAQ ZGNX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  216 (Vote Outperform)
Underperform Votes:  123 (Vote Underperform)
Total Votes:  339
MarketBeat's community ratings are surveys of what our community members think about Zogenix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Zogenix (NASDAQ:ZGNX)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 5 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $46.00 (25.85% upside)

Consensus Price Target History for Zogenix (NASDAQ:ZGNX)

Price Target History for Zogenix (NASDAQ:ZGNX)

Analysts' Ratings History for Zogenix (NASDAQ:ZGNX)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/8/2017MizuhoReiterated RatingBuy$51.00N/AView Rating Details
10/2/2017Leerink SwannReiterated RatingOutperform -> Outperform$20.00 -> $50.00HighView Rating Details
9/29/2017Stifel NicolausReiterated RatingBuy$26.00 -> $55.00N/AView Rating Details
9/29/2017William BlairUpgradeMarket Perform -> OutperformN/AView Rating Details
3/11/2017AegisReiterated RatingBuy$28.00N/AView Rating Details
9/21/2016Brean CapitalReiterated RatingBuy$28.00N/AView Rating Details
(Data available from 11/18/2015 forward)

Earnings

Earnings History and Estimates Chart for Zogenix (NASDAQ:ZGNX)

Earnings by Quarter for Zogenix (NASDAQ:ZGNX)

Earnings History by Quarter for Zogenix (NASDAQ ZGNX)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017($0.89)($0.90)$3.48 million$7.10 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.88)($0.85)$4.23 million$2.70 millionViewListenView Earnings Details
11/7/2016Q3($0.96)($0.69)$3.10 million$6.57 millionViewListenView Earnings Details
8/9/2016Q216($0.81)($0.76)$5.36 million$2.10 millionViewN/AView Earnings Details
5/10/2016Q116($0.62)($0.42)$4.90 million$9.20 millionViewListenView Earnings Details
3/10/2016Q415($0.69)($0.36)$6.39 million$6.10 millionViewListenView Earnings Details
11/9/2015Q315($0.74)($0.65)$5.90 million$9.12 millionViewN/AView Earnings Details
8/10/2015Q215($0.77)$3.78$5.13 million$7.40 millionViewListenView Earnings Details
5/11/2015Q115($0.13)($0.15)$8.54 million$4.60 millionViewListenView Earnings Details
3/10/2015Q414($0.11)($0.13)$11.50 million$14.90 millionViewListenView Earnings Details
11/6/2014Q314($0.16)($0.15)$8.30 million$8.80 millionViewListenView Earnings Details
8/5/2014Q214($0.16)($0.19)$9.84 million$9.16 millionViewListenView Earnings Details
5/8/2014Q114($0.17)($0.20)$8.71 million$7.70 millionViewListenView Earnings Details
3/5/2014Q413($0.09)($0.13)$8.68 million$9.90 millionViewListenView Earnings Details
11/4/2013Q313($0.09)($0.12)$9.33 million$7.20 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.15)($0.13)$8.63 million$8.90 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.14)($0.21)$9.28 million$7.00 millionViewListenView Earnings Details
3/15/2013Q4 2012($0.17)($0.16)$9.87 million$9.50 millionViewListenView Earnings Details
11/8/2012Q312($0.16)($0.16)$9.98 million$8.50 millionViewN/AView Earnings Details
8/8/2012($0.28)($0.26)ViewN/AView Earnings Details
5/14/2012($0.14)($0.16)ViewN/AView Earnings Details
3/8/2012($0.36)($0.36)ViewN/AView Earnings Details
11/10/2011($0.55)($0.59)ViewN/AView Earnings Details
5/16/2011($0.50)($0.56)ViewN/AView Earnings Details
3/3/2011($0.62)($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Zogenix (NASDAQ:ZGNX)
2017 EPS Consensus Estimate: ($2.82)
2018 EPS Consensus Estimate: ($3.63)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.85)($0.85)($0.85)
Q3 20172($0.99)($0.93)($0.96)
Q4 20172($1.22)($0.80)($1.01)
Q1 20182($0.97)($0.77)($0.87)
Q2 20182($0.94)($0.85)($0.90)
Q3 20182($0.98)($0.74)($0.86)
Q4 20182($1.02)($0.98)($1.00)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Zogenix (NASDAQ:ZGNX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Zogenix (NASDAQ ZGNX)

Insider Ownership Percentage: 5.00%
Institutional Ownership Percentage: 62.41%
Insider Trades by Quarter for Zogenix (NASDAQ:ZGNX)
Institutional Ownership by Quarter for Zogenix (NASDAQ:ZGNX)

Insider Trades by Quarter for Zogenix (NASDAQ ZGNX)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/3/2017Life Sciences Maste PerceptiveMajor ShareholderBuy300,000$37.50$11,250,000.00View SEC Filing  
9/29/2017Life Sciences Maste PerceptiveMajor ShareholderBuy222,055$32.83$7,290,065.65View SEC Filing  
6/30/2017Life Sciences Maste PerceptiveMajor ShareholderBuy175,653$14.45$2,538,185.85View SEC Filing  
3/16/2017Renee P TannenbaumDirectorBuy5,000$11.00$55,000.00View SEC Filing  
12/15/2015Roger HawleyDirectorBuy10,000$13.74$137,400.00View SEC Filing  
6/13/2014Cam L GarnerDirectorBuy30,000$1.66$49,800.00View SEC Filing  
6/3/2014Ann D RhoadsCFOSell19,229$2.10$40,380.90View SEC Filing  
6/3/2014Roger HawleyCEOSell25,078$2.10$52,663.80View SEC Filing  
6/3/2014Stephen J FarrCOOSell20,900$2.10$43,890.00View SEC Filing  
11/20/2013Richard Scott ShivelyInsiderBuy67,000$2.79$186,930.00View SEC Filing  
12/13/2012Cynthia Y RobinsonInsiderBuy50,000$1.17$58,500.00View SEC Filing  
12/12/2012Ann D RhoadsCFOBuy17,500$1.19$20,825.00View SEC Filing  
12/12/2012Cam L GarnerDirectorBuy70,000$1.21$84,700.00View SEC Filing  
12/11/2012Erle T MastDirectorBuy10,000$1.15$11,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Zogenix (NASDAQ:ZGNX)

Latest Headlines for Zogenix (NASDAQ ZGNX)

Source:
DateHeadline
Zacks: Analysts Expect Zogenix, Inc. (ZGNX) Will Post Earnings of -$1.01 Per ShareZacks: Analysts Expect Zogenix, Inc. (ZGNX) Will Post Earnings of -$1.01 Per Share
www.americanbankingnews.com - November 16 at 5:30 PM
Zogenix to Present at Stifel 2017 Healthcare ConferenceZogenix to Present at Stifel 2017 Healthcare Conference
finance.yahoo.com - November 16 at 10:29 AM
FY2017 EPS Estimates for Zogenix, Inc. (ZGNX) Lowered by AnalystFY2017 EPS Estimates for Zogenix, Inc. (ZGNX) Lowered by Analyst
www.americanbankingnews.com - November 10 at 12:26 PM
FY2017 EPS Estimates for Zogenix, Inc. Decreased by Analyst (ZGNX)FY2017 EPS Estimates for Zogenix, Inc. Decreased by Analyst (ZGNX)
www.americanbankingnews.com - November 10 at 12:26 PM
Research Analysts Offer Predictions for Zogenix, Inc.s Q2 2018 Earnings (ZGNX)Research Analysts Offer Predictions for Zogenix, Inc.'s Q2 2018 Earnings (ZGNX)
www.americanbankingnews.com - November 9 at 12:34 PM
Edited Transcript of ZGNX earnings conference call or presentation 7-Nov-17 9:30pm GMTEdited Transcript of ZGNX earnings conference call or presentation 7-Nov-17 9:30pm GMT
finance.yahoo.com - November 9 at 10:49 AM
Mizuho Reiterates Buy Rating for Zogenix, Inc. (ZGNX)Mizuho Reiterates Buy Rating for Zogenix, Inc. (ZGNX)
www.americanbankingnews.com - November 8 at 10:26 PM
Zogenixs (ZGNX) CEO Stephen Farr on Q3 2017 Results - Earnings Call TranscriptZogenix's (ZGNX) CEO Stephen Farr on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 8 at 2:25 AM
Zogenix reports 3Q lossZogenix reports 3Q loss
finance.yahoo.com - November 7 at 9:24 PM
Zogenix, Inc. to Host Earnings CallZogenix, Inc. to Host Earnings Call
finance.yahoo.com - November 7 at 4:19 PM
Zogenix Provides Corporate Update and Reports Third Quarter 2017 Financial ResultsZogenix Provides Corporate Update and Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 7 at 4:19 PM
What's Behind GW Pharmaceuticals' 6.4% Gain in October?What's Behind GW Pharmaceuticals' 6.4% Gain in October?
finance.yahoo.com - November 6 at 3:36 PM
Zogenix to Release Third Quarter 2017 Financial Results and Host Conference Call and Webcast on November 7Zogenix to Release Third Quarter 2017 Financial Results and Host Conference Call and Webcast on November 7
finance.yahoo.com - October 31 at 12:46 PM
Zogenix, Inc. (ZGNX) Set to Announce Quarterly Earnings on MondayZogenix, Inc. (ZGNX) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - October 30 at 9:37 AM
Technical Snapshots for These Drug Makers Stocks -- Immune Pharma, Zogenix, Shire, and AbbVieTechnical Snapshots for These Drug Makers Stocks -- Immune Pharma, Zogenix, Shire, and AbbVie
www.bizjournals.com - October 27 at 5:18 PM
ETFs with exposure to Zogenix, Inc. : October 27, 2017ETFs with exposure to Zogenix, Inc. : October 27, 2017
finance.yahoo.com - October 27 at 5:18 PM
Technical Snapshots for These Drug Makers Stocks -- Immune Pharma, Zogenix, Shire, and AbbVie - PR Newswire (press release)Technical Snapshots for These Drug Makers Stocks -- Immune Pharma, Zogenix, Shire, and AbbVie - PR Newswire (press release)
www.prnewswire.com - October 27 at 7:56 AM
Zogenix, Inc. (ZGNX) Receives Consensus Rating of "Buy" from BrokeragesZogenix, Inc. (ZGNX) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - October 27 at 5:46 AM
22 Stocks To Watch After President Trump Declares Opioid Epidemic A National Health Emergency22 Stocks To Watch After President Trump Declares Opioid Epidemic A National Health Emergency
feeds.benzinga.com - October 26 at 3:57 PM
High Seizure Frequency in Children with Dravet Syndrome Negatively Impacts Quality of Life, New International Caregiver Survey FindsHigh Seizure Frequency in Children with Dravet Syndrome Negatively Impacts Quality of Life, New International Caregiver Survey Finds
finance.yahoo.com - October 19 at 10:34 AM
ETFs with exposure to Zogenix, Inc. : October 16, 2017ETFs with exposure to Zogenix, Inc. : October 16, 2017
finance.yahoo.com - October 17 at 9:32 AM
Interim Survey Results Demonstrate Impact on Siblings of Children Suffering from Severe EpilepsyInterim Survey Results Demonstrate Impact on Siblings of Children Suffering from Severe Epilepsy
finance.yahoo.com - October 16 at 8:22 AM
Daily Insider Ratings Round Up 10/3/17: ZGNX, SOR - Seeking AlphaDaily Insider Ratings Round Up 10/3/17: ZGNX, SOR - Seeking Alpha
seekingalpha.com - October 6 at 3:36 PM
ETFs with exposure to Zogenix, Inc. : October 5, 2017ETFs with exposure to Zogenix, Inc. : October 5, 2017
finance.yahoo.com - October 6 at 10:05 AM
Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesZogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - October 6 at 10:05 AM
Q3 2017 Earnings Forecast for Zogenix, Inc. (ZGNX) Issued By Leerink SwannQ3 2017 Earnings Forecast for Zogenix, Inc. (ZGNX) Issued By Leerink Swann
www.americanbankingnews.com - October 6 at 7:14 AM
Zogenix closes equity offering, raises almost $289M; shares down 2% after hoursZogenix closes equity offering, raises almost $289M; shares down 2% after hours
seekingalpha.com - October 5 at 4:47 PM
Zogenix: Investors Bet Heavy On ZX008 For Dravet SyndromeZogenix: Investors Bet Heavy On ZX008 For Dravet Syndrome
seekingalpha.com - October 4 at 6:01 PM
Zogenix, Inc. – Value Analysis (NASDAQ:ZGNX) : October 2, 2017Zogenix, Inc. – Value Analysis (NASDAQ:ZGNX) : October 2, 2017
finance.yahoo.com - October 4 at 6:01 PM
Zogenix Prices Public Offering of Common StockZogenix Prices Public Offering of Common Stock
finance.yahoo.com - October 4 at 6:01 PM
A Drug That May Be Better Than Marijuana Sent This Company's Stock Soaring 196% in SeptemberA Drug That May Be Better Than Marijuana Sent This Company's Stock Soaring 196% in September
finance.yahoo.com - October 4 at 1:00 PM
Todays Research Reports on Trending Tickers: GW Pharmaceuticals and ZogenixToday's Research Reports on Trending Tickers: GW Pharmaceuticals and Zogenix
finance.yahoo.com - October 4 at 1:00 PM
Zogenix, Inc. :ZGNX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017Zogenix, Inc. :ZGNX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017
finance.yahoo.com - October 4 at 1:00 PM
Implied Volatility Surging for Zogenix (ZGNX) Stock Options - NasdaqImplied Volatility Surging for Zogenix (ZGNX) Stock Options - Nasdaq
www.nasdaq.com - October 3 at 4:30 PM
Zogenix Brings About Rivalry For Rare Epilepsy Drug - Seeking AlphaZogenix Brings About Rivalry For Rare Epilepsy Drug - Seeking Alpha
seekingalpha.com - October 3 at 4:30 PM
Implied Volatility Surging for Zogenix (ZGNX) Stock OptionsImplied Volatility Surging for Zogenix (ZGNX) Stock Options
finance.yahoo.com - October 3 at 4:30 PM
Life Sciences Maste Perceptive Acquires 300,000 Shares of Zogenix, Inc. (ZGNX) StockLife Sciences Maste Perceptive Acquires 300,000 Shares of Zogenix, Inc. (ZGNX) Stock
www.americanbankingnews.com - October 3 at 4:28 PM
Insider Buying: Zogenix, Inc. (ZGNX) Major Shareholder Purchases 222,055 Shares of StockInsider Buying: Zogenix, Inc. (ZGNX) Major Shareholder Purchases 222,055 Shares of Stock
www.americanbankingnews.com - October 3 at 10:18 AM
How Risky Is GW Pharmaceuticals Stock After Zogenixs Big News?How Risky Is GW Pharmaceuticals Stock After Zogenix's Big News?
www.fool.com - October 3 at 7:42 AM
Zogenix Soars 10% Today Despite Diluting InvestorsZogenix Soars 10% Today Despite Diluting Investors
www.fool.com - October 2 at 3:24 PM
What Do Zogenix Drug Study Results Mean For GW Pharmaceuticals Epidiolex?What Do Zogenix Drug Study Results Mean For GW Pharmaceuticals' Epidiolex?
feeds.benzinga.com - October 2 at 2:14 PM
Leerink Swann Boosts Zogenix, Inc. (ZGNX) Price Target to $50.00Leerink Swann Boosts Zogenix, Inc. (ZGNX) Price Target to $50.00
www.americanbankingnews.com - October 2 at 9:12 AM
Q1 2018 Earnings Forecast for Zogenix, Inc. (ZGNX) Issued By William BlairQ1 2018 Earnings Forecast for Zogenix, Inc. (ZGNX) Issued By William Blair
www.americanbankingnews.com - October 2 at 4:56 AM
Zogenix, Inc. (ZGNX) Given Average Recommendation of "Buy" by AnalystsZogenix, Inc. (ZGNX) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - October 2 at 2:38 AM
Zogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome - GlobeNewswire (press release)Zogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome - GlobeNewswire (press release)
globenewswire.com - October 1 at 5:40 AM
Zogenix ZX008 Is The Real Deal - Seeking AlphaZogenix' ZX008 Is The Real Deal - Seeking Alpha
seekingalpha.com - September 30 at 9:10 PM
3 Biotech Stocks That Soared This Week: Are They Buys?3 Biotech Stocks That Soared This Week: Are They Buys?
www.fool.com - September 30 at 11:35 AM
UPDATE: Zogenix stock rockets 195% premarket on news of positive epilepsy drug trialUPDATE: Zogenix stock rockets 195% premarket on news of positive epilepsy drug trial
www.marketwatch.com - September 30 at 11:00 AM
UPDATE: William Blair Upgrades Zogenix, Inc. (ZGNX) to Outperform - StreetInsider.comUPDATE: William Blair Upgrades Zogenix, Inc. (ZGNX) to Outperform - StreetInsider.com
www.streetinsider.com - September 29 at 10:29 PM
Zogenix (ZGNX) Phase 3 Clinical Trial of ZX008 in Dravet Syndrome Met Primary ObjectiveZogenix (ZGNX) Phase 3 Clinical Trial of ZX008 in Dravet Syndrome Met Primary Objective
www.streetinsider.com - September 29 at 5:24 PM

Social Media

Financials

Chart

Zogenix (NASDAQ ZGNX) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.